Manish R. Patel
Expertise in
22
conditions

Dr. Manish R. Patel

Oncology | Otolaryngology
M Health Fairview Masonic Cancer Clinic
909 Fulton Street Southeast, 
Minneapolis, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
M Health Fairview Masonic Cancer Clinic
909 Fulton Street Southeast, 
Minneapolis, MN 

Overview

Manish Patel is an Oncologist and an Otolaryngologist practicing medicine in Minneapolis, Minnesota.

Dr. Patel is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Gastrostomy, and Pancreatectomy.

Dr. Patel is board certified in Medical Oncology: American Board Of Internal Medicine, 2009. He is actively involved in clinical research, participating in 42 clinical trials. Dr. Patel is currently accepting new patients.

Specialties

Oncology
Otolaryngology

Licenses

Internal Medicine in MN

Board Certifications

Medical Oncology: American Board Of Internal Medicine, 2009

Fellowships

University of Minnesota-Hematology and Oncology, Hematology/Oncology - 2009
University of Minnesota-Hematology and Oncology, Research - 2006,2010
Winthrop-University Hospital, Research - 2005

Hospital Affiliations

Fairview Lakes Health Services
M Health Fairview University Of Mn Medical Center
Fairview Northland Regional Hospital
M Health Fairview Ridges Hospital
M Health Fairview St John's Hospital

Languages Spoken

English
Gujarati 

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford Health
  • HMO
  • PPO
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

M Health Fairview Masonic Cancer Clinic
909 Fulton Street Southeast, Minneapolis, MN 55455

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

40 Clinical Trials

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug
Study Drugs: ART0380, Gemcitabine
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Goserelin acetate, Pembrolizumab
Study Phase: Phase 2
Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors
Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Biological
Study Drugs: VV1, Cemiplimab
Study Phase: Phase 2
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Completed
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2026
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Biological
Study Drugs: ALT-803, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

M Health Fairview Masonic Cancer Clinic

909 Fulton Street Southeast, 
Minneapolis, MN 
 (0.1 miles away)
612-676-4200
Languages Spoken:
English, French, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Emmanuel Antonarakis is an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Antonarakis is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, PIK3CA-Related Overgrowth Spectrum, Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Antonarakis is board certified in Medical Oncology: American Board Of Internal Medicine, 2009. Dr. Antonarakis is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

M Health Fairview Masonic Cancer Clinic

909 Fulton Street Southeast, 
Minneapolis, MN 
 (0.1 miles away)
612-676-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Skubitz is an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Skubitz is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Liposarcoma, Alveolar Soft Part Sarcoma, and Splenectomy. Dr. Skubitz is board certified in Medical Oncology: American Board Of Internal Medicine, 1985 and Internal Medicine: American Board Of Internal Medicine, 1979. Dr. Skubitz is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

M Health Fairview Masonic Cancer Clinic

909 Fulton Street Southeast, 
Minneapolis, MN 
 (0.1 miles away)
612-676-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Kratzke is an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Kratzke is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Endoscopy. Dr. Kratzke is board certified in Internal Medicine: American Board Of Internal Medicine, 1986 and Medical Oncology: American Board Of Internal Medicine, 1991. Dr. Kratzke is currently accepting new patients.

Frequently Asked Questions about Dr. Manish R. Patel

How do I make an appointment with Dr. Manish R. Patel?

You can book an appointment with Dr. Manish R. Patel by calling their office at 612-676-4200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Manish R. Patel a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Manish R. Patel is classified as an Distinguished expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Manish R. Patel specialize in?

While Dr. Manish R. Patel is a Oncology, they have specific expertise in Pleuropulmonary Blastoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Manish R. Patel accept my insurance?

Dr. Manish R. Patel accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 612-676-4200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile